Drug Profile
BI 416970
Alternative Names: BI-416970Latest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Undefined(In volunteers) in Germany (PO, Liquid)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Undefined(In volunteers) in Germany (PO, Tablet)
- 28 Apr 2016 Phase-I development is ongoing in Germany